All posts by: Michael Zand

Landmark gene therapy for hereditary blindness closes in on FDA approval – New Atlas

New AtlasLandmark gene therapy for hereditary blindness closes in on FDA approvalNew AtlasBack in August, the FDA approved the first gene therapy for general use in the United States. That particular treatment, for cancer, was beset by controversy due … Continue reading

— Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer – Nasdaq

CORRECTING and REPLACING — Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat … – GlobeNewswire (press release)

Novel gene therapy approach to treating methamphetamine abuse – EurekAlert (press release)

Novel gene therapy approach to treating methamphetamine abuseEurekAlert (press release)13, 2017 — While there are no FDA-approved medicines to treat methamphetamine (meth) use disorders, researchers are reporting early findings of a second-generation … Continue reading

Oncologists must be prepared to inform patients about risks, benefits of CAR T-cell therapies – Healio

Oncologists must be prepared to inform patients about risks, benefits of CAR T-cell therapiesHealioPorter, who gave an update of chimeric antigen receptor (CAR) T-cell therapies, said he felt it was necessary to explain the excitement surrounding the r… Continue reading

Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer – GlobeNewswire (press release)

Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian CancerGlobeNewswire (press release)LAWRENCEVILLE, N.J., Nov. 13, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ:CLSN), an oncology drug dev… Continue reading